Sequenom Shares Fall After Revised Test Data

Sequenom's shares fell for a second day straight and are down nearly 24 percent over the past two days after it reported revised data on its SEQureDx test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.